Nordion, Manufacturer of TheraSphere®, to Host Educational Symposium at the 2013 Gastrointestinal Cancers Symposium

  Nordion, Manufacturer of TheraSphere®, to Host Educational Symposium at the
  2013 Gastrointestinal Cancers Symposium

Agenda includes new HCC clinical data and an update on TheraSphere® Phase III
                               clinical trials

Business Wire

OTTAWA, Ontario -- January 24, 2013

Nordion Inc. (TSX: NDN) (NYSE: NDZ),a leading provider of products and
services for the prevention, diagnosis and treatment of disease, announced
today it is hosting an educational symposium titled “The Expanding Role of
Radioembolization for the Treatment of Hepatocellular Carcinoma (HCC): Latest
Information about Radioembolization, Yttrium-90 (Y-90) Glass Microspheres in
HCC and an Update on Phase III Clinical Trials.” The symposium, designed to
educate referring physicians, including Medical Oncologists, Hepatologists and
Gastroenterologists, is being held at this year’s 2013 Gastrointestinal
Cancers Symposium in San Francisco from January 24 – 26, 2013.

Three leading physicians will present the following information to attendees:

  *“Y-90 Glass Microspheres in HCC - What do we Know?” by Dr. Riad Salem,
    Interventional Oncologist, Northwestern University, Chicago, Illinois. Dr
    Salem will provide an overview of clinical utility of Y-90 glass
    microspheres including a review of the Phase III clinical trial program
    for TheraSphere®.
  *“TheraSphere® vs. transarterial chemoembolization (TACE) Data Analysis in
    Intermediate HCC – What did we learn?” by Dr. Lewis Roberts,
    Gastroenterologist,  Mayo Clinic, Rochester, Minnesota. Dr. Roberts will
    present the results of a retrospective analysis of TheraSphere® ^  vs.
    TACE in patients with unresectable HCC.
  *“Prospective Phase II Study on Intermediate and Advanced HCC – Experience
    at Milan, Italy” by Dr. Sherrie Bhoori, Hepatologist, Istituto Tumori,
    Milan, Italy. Dr. Bhoori will discuss Istituto Tumori’s prospective Phase
    II data published in Hepatology and how this study led to the development
    of the Phase III YES-P trial.

About TheraSphere®

TheraSphere^® is a liver cancer therapy that consists of millions of small
glass beads (20 to 30 micrometers in diameter) containing radioactive Y-90.
The product is injected by physicians into the artery of the patient’s liver
through a catheter, which allows the treatment to be delivered directly to the
tumour via blood flow.

In the US, TheraSphere^® is used to treat patients with hepatocellular
carcinoma (HCC) who can have appropriately positioned hepatic arterial
catheters, and can be used as a bridge to surgery or transplantation in these
patients. It is also indicated for the treatment of HCC patients with partial
or branch portal vein thrombosis or occlusion when clinical evaluation
warrants the treatment. TheraSphere^® is approved by the U.S. Food and Drug
Administration (FDA) under a Humanitarian Device Exemption (HDE). HDE
approvals are based on demonstrated safety and probable clinical benefit.
However, effectiveness of the indication for use has not been established.

TheraSphere^® is used in the European Union and in Canada for the treatment of
hepatic neoplasia in patients who have appropriately positioned arterial
catheters.

Common side effects include mild to moderate fatigue, pain and nausea for
about a week. Physicians describe these symptoms as similar to those of the
flu. Some patients experience some loss of appetite and temporary changes in
several blood tests. For details on rare or more severe side effects, please
refer to the TheraSphere^® package insert/instructions for use at
www.nordion.com/therasphere.

About Nordion Inc.

Nordion Inc. (TSX: NDN) (NYSE: NDZ) is a global health science company that
provides market-leading products used for the prevention, diagnosis and
treatment of disease. We are a leading provider of targeted therapies,
sterilization technologies and medical isotopes that benefit the lives of
millions of people in more than 60 countries around the world. Our products
are used daily by pharmaceutical and biotechnology companies, medical-device
manufacturers, hospitals, clinics and research laboratories. Nordion has
approximately 500 highly skilled employees worldwide. Find out more at
www.nordion.com and follow us at http://twitter.com/NordionInc.

Contact:

Nordion Inc.
MEDIA:
Shelley Maclean, 613-592-3400 x. 2414
shelley.maclean@nordion.com
or
INVESTORS:
Ana Raman, 613-595-4580
investor.relations@nordion.com